Chemomab Therapeutics Ltd. (CMMB) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Chemomab Therapeutics Ltd.
Sector
Healthcare
Industry
Biotechnology
Employees
12
First IPO Date
February 12, 2019
Key Executives
| Name | Title | Pay | Year Born |
| Adi Mor George | Co-Founder, Chief Scientific Officer, Chief Executive Officer & Executive Director | 800,000 | 1982 |
| Sigal Fattal | Chief Financial Officer | 600,000 | 1971 |
| John Lawler | Chief Development Officer | 728,500 | N/A |
| Jack Lawler | Chief Development Officer | 728,500 | N/A |
| Barbara Lindheim | Consulting Vice President of Investor & Public Relations, Strategic Communications | 0 | 1950 |
| David Weiner | Interim Chief Medical Officer | 0 | 1965 |
Description
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
